Visiopharm Overview
- Founded
- 2001
- Status
- Acquired/Merged
- Employees
- 86
- Latest Deal Type
- Later Stage VC
- Investors
- 6
Visiopharm General Information
Description
Developer of pioneering image analysis and precision pathology tools designed to support researchers, diagnostics, drug development, and the development of companion diagnostics. The company uses artificial intelligence and deep learning to deliver tissue data mining tools, precision results, standardization of tissue data, and improved productivity, the solutions are agnostic with respect to scanner format and can easily be integrated with digital infrastructure and workflows, enabling medical practitioners to operate on a wide variety of virtual slide microscopes.
Contact Information
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Parent Company
Primary Office
- Agern Allé 24
- 2970 Hørsholm
- Denmark
+45 88 00 00 00
Visiopharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 01-Sep-2020 | Completed | Generating Revenue | |||
| 3. Merger/Acquisition | 02-Mar-2020 | 000.00 | Completed | Generating Revenue | ||
| 2. Later Stage VC | 23-Aug-2018 | $15.5M | $15.5M | Completed | Generating Revenue | |
| 1. Later Stage VC | 05-Oct-2007 | Completed | Generating Revenue |
Visiopharm Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of pioneering image analysis and precision pathology tools designed to support researchers, diagnostics, drug
Decision/Risk Analysis
Hørsholm, Denmark
86
As of 2020
000.00
0000000000 0
00000000
is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dol
0000000000 000000000
Tolochenaz, Switzerland
00
As of 0000
000.00
000
0000-00-00
00000000000
000.00
000000 0
it esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
00000 0000000000
NM
00
As of 0000
000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialVisiopharm Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lunaphore Technologies | Venture Capital-Backed | Tolochenaz, Switzerland | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 0000 | Angel-Backed | NM | 00 | 000000000 |
Visiopharm Executive Team (12)
Visiopharm Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Claus Møller MD | The ATP Group | Board Member | 000 0000 |
| Henrik Stender Ph.D | Self | Board Member | 000 0000 |
| Johan Hansen | Visiopharm | Co-Founder, Chief Technical Officer & Board Member | 000 0000 |
| Martin Bonde Ph.D | Self | Board Member | 000 0000 |
| Michael Grunkin Ph.D | Visiopharm | Co-Founder, Chief Executive Officer, Managing Director & Board Member | 000 0000 |
Visiopharm Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialVisiopharm Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000 0000000 | 01-Dec-2016 | 000000000000000000 | Other Devices and Supplies | 0000000 0000000 00.0 | |
| Digital Pathology Consultants | 08-Dec-2012 | Merger/Acquisition | Consulting Services (B2B) | 0000000 0000000 00.0 |